Further validation of the flexibility of the Self Assembling Vaccine (SAV) platform. Important step in improving Pandemic Preparedness

NEW YORK, NEW YORK, USA, January 11, 2022 /EINPresswire.com/ -- Voltron Therapeutics, Inc. a Laidlaw Venture Partners Portfolio Company, today announced that it has tested its rapid development Self Assembling Vaccine (SAV) platform in real time with the emergence of the Omicron variant.

Key accomplishments include:
- Reviewed the viral sequence of Omicron and assessed our peptide/immune coverage
- Determined the complexity of altering Voltron’s vaccine. Crucially, none of the original
11 peptides needed to be removed and only one peptide was added. This would make
modification to our vaccine relatively simple and expected to be effective in protecting
against the Omicron variant as well as prior variants
- Our assessment indicates that it would take 4 weeks to identify and synthesize the new
peptide and another 4 weeks to complete the assembly of the new vaccine
- Per sequence analysis, Voltron’s vaccine evokes a broader array of immune responses
against both spike and non-spike proteins targets in covid-19 making it more challenging
for the virus to evade through mutation around a single functional component

Voltron’s vaccine platform was designed by scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) and Harvard Medical School, in anticipation of emerging infectious diseases (EID) including pandemic respiratory viruses, not in response to one specific pathogen. It is designed to address current and future needs for EID preparedness on several levels. Importantly, Voltron’s platform provides a nimble and safe solution that can be quickly developed against emerging pathogens, is easy to deploy and stockpile, and is broadly applicable to a range of viral pathogens.

Dr. Mark Poznansky, Director of VIC at MGH stated, “The plasticity of the COVID-19 genome is greater than anticipated. The breadth of changes in mutations that have occurred in Omicron in comparison to the Delta variant is scientifically remarkable. Many of these mutations are concentrated in areas where monoclonal antibodies and vaccines are currently directed. It is apparent to us that broadly targeting the viral proteome is important and our next generation vaccine needs to be adaptable in a short time frame to address emerging variants of concern.”“Omicron further demonstrates the need for new vaccine platforms and/or approaches whose abilities are as flexible as the virus itself,” said Patrick Gallagher, CEO of Voltron Therapeutics. We immediately tested our platform and our target product profile with the emergence of
Omicron. This profile, which includes broad immune targeting, innate and cellular immune responses, improved durability of protection, flexibility/ ability to respond rapidly to variants of concern, and easier deployment, nationally and globally, could provide the needed flexibility to address new or mutating pathogens.”

James Ahern, founding partner of LVP, concluded that, “the results of Voltron’s efforts to simulate our rapid vaccine development efforts in a live ‘fire-drill’ setting are very encouraging. They demonstrate LVP’s ability to build a senior team capable of immediately addressing appropriate peptide selection, synthesis and manufacturing, and clinical development considerations to address emerging infectious diseases and viral mutations. Our platform is designed for reproduceable results, regardless of virus. This provides us the ability to quickly explore vaccines that could have a meaningful impact on patients and the healthcare system.”

About Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians,
this technology has shown in certain pre-clinical studies initial proof of concept in two
infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and
HPV Related Cancers).
For more information please visit www.voltrontx.com.

About HaloVax™, LLC
HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ: HOTH) The mission of HaloVax is to develop a novel, SelfAssembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne.

To learn more, please
visit www.hoththerapeutics.com.

About Laidlaw & Company

Laidlaw & Company is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private institutions, public institutions, and high net worth individual investors. Laidlaw & Company (U.K.) Ltd., a broker-dealer registered with FINRA in the United States, clears on a fully disclosed basis through Stone X, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited, an affiliate of Laidlaw & Company, is authorized by the Financial Conduct Authority (FCA) in the United Kingdom. Laidlaw Wealth Management and Laidlaw Private Equity, LLC are affiliates of Laidlaw &
Company (UK) Ltd.

Laidlaw Venture Partners is a DBA, of Laidlaw Private Equity.
For more information, please visit: https://laidlawltd.com/

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity,
performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Investor Contacts:
Matt Duffy
President
Voltron Therapeutics, Inc.
mduffy@luciuspartnersllc.com
646.335.5923

Richard Calhoun
Laldlaw & Co
+1 212-953-4937
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.